Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.3.16 (
calcineurin
)
17,112
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The rising incidence and poor prognosis of colorectal cancer have aroused substantial interest in novel chemopreventive strategies. Interestingly, treatment of ulcerative colitis with mesalazine, which displays few side effects during long-term treatment, is associated with a reduced incidence of colorectal cancer, but its molecular mechanism is not known. The effect of mesalazine on the Wnt/
beta-catenin
pathway was studied in colorectal cancer cell lines to find a molecular basis underlying its chemopreventive features. Mesalazine affects the Wnt/
beta-catenin
pathway in adenomatous polyposis coli mutated cells with intact
beta-catenin
, judged by luciferase reporter assays. Furthermore, mesalazine treatment reduced expression of nuclear
beta-catenin
and Wnt/
beta-catenin
target genes, and increased
beta-catenin
phosphorylation. This effect on the Wnt/
beta-catenin
pathway is mediated via protein phosphatase 2A (
PP2A
): increased phosphorylation of
PP2A
after mesalazine treatment is observed, which coincides with decreased
PP2A
enzymatic activity. The inhibition of
PP2A
enzymatic activity by mesalazine is essential for its effect on the Wnt/
beta-catenin
pathway, as shown by transient transfection with siPP2A and mutant
PP2A
. This study shows, using concentrations of mesalazine identical to concentrations seen in patients with inflammatory bowel disease, that mesalazine inhibits the Wnt/
beta-catenin
pathway via inhibition of
PP2A
.
...
PMID:Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. 1672 34
Nonsteroidal anti-inflammatory drugs show chemopreventive efficacy in colon cancer, but the mechanism behind this remains unclear. Elucidating this mechanism is seen as vital to the development of new chemopreventive agents. We studied the effects of aspirin on the oncogenic Wnt/
beta-catenin
pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of
beta-catenin
by immunoblotting. Furthermore, the ubiquitination and cytoplasmic levels of
beta-catenin
were assessed by immunoblotting, and also the localization of
beta-catenin
was shown by green fluorescent protein-tagged
beta-catenin
and time-lapse fluorescent imaging. Importantly, aspirin treatment caused increased phosphorylation of protein phosphatase 2A (
PP2A
), an event associated with inhibition of
PP2A
enzymatic activity, which was confirmed by a reduction in enzymatic
PP2A
activity. Moreover, this inhibition of
PP2A
enzymatic activity was essential for the effects of aspirin on the Wnt/
beta-catenin
pathway as shown by transient transfection with
PP2A
constructs. The findings in this article provide a molecular explanation for the efficacy of aspirin in chemoprevention of colorectal cancer and shows biochemical evidence that
PP2A
is an important regulator of Wnt/
beta-catenin
pathway activity in these cells.
...
PMID:Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. 1687 61
Epilepsy of progressive myoclonus type 2 gene A (EPM2A) encodes a dual specificity protein phosphatase called Laforin. Laforin is also a tumor suppressor that dephosphorylates GSK3beta at the critical Ser9 position and regulates Wnt signaling. The epilepsy-causing mutations have a deleterious effect on phosphatase activity, regardless of whether they locate in the carbohydrate-binding domain (CBD) at the N terminus or the dual specificity phosphatase domain (DSPD) at the C terminus. How mutations outside the DSPD reduce the phosphatase activity of Laforin remains unexplained. Here we report that Laforin expressed in mammalian cells forms dimers that are highly resistant to SDS treatment. Deleting CBD completely abolished the dimerization and phosphatase activity of Laforin. Moreover, all of the naturally occurring Laforin mutations tested impaired laforin GSK3beta dephosphorylation at Ser9 dimerization, and
beta-catenin
accumulation in nucleus. Our results demonstrate a critical role of dimerization in Laforin function and suggest an important new dimension in
protein phosphatase
function and in molecular pathogenesis of Lafora's disease.
...
PMID:Dimerization of Laforin is required for its optimal phosphatase activity, regulation of GSK3beta phosphorylation, and Wnt signaling. 1697 87
The protein phosphatase 2A (
PP2A
) is a serine/threonine phosphatase involved in the regulation of multiple signaling pathways including the Wnt/
beta-catenin
and the ERK pathways. To understand the complex signaling networking associated with
PP2A
, we searched proteins interacting with the catalytic subunit of protein phosphatase 2A (PP2Ac) by a pull-down analysis followed by 2-D gel electrophoresis and proteomic analyses. The probability of identification of the proteins interacting with PP2Ac was increased by searching proteins differently interacting with PP2Ac according to stimulation of Wnt3a, which regulates both the Wnt/
beta-catenin
and the ERK pathways. Around 100 proteins, pulled-down by His-tagged PP2Ac, were identified in 2-D gels stained with CBB. By MALDI-TOF-MS analyses of 45 protein spots, we identified several proteins that were previously known to interact with
PP2A
, such as Axin and CaMK IV. In addition, we also identified many proteins that potentially interact with PP2Ac. The interactions of several candidate proteins, such as tuberous sclerosis complex 2, RhoB, R-Ras, and Nm23H2, with PP2Ac, were confirmed by in vitro binding analyses and/or coimmunoprecipitation experiments.
...
PMID:Identification of proteins interacting with the catalytic subunit of PP2A by proteomics. 1716 75
The Wnt/
beta-catenin
signaling pathway is critical in both cellular proliferation and organismal development. However, how the
beta-catenin
degradation complex is inhibited upon Wnt activation remains unclear. Using a directed RNAi screen we find that
protein phosphatase
1 (PP1), a ubiquitous serine/threonine phosphatase, is a novel potent positive physiologic regulator of the Wnt/
beta-catenin
signaling pathway. PP1 expression synergistically activates, and inhibition of PP1 inhibits, Wnt/
beta-catenin
signaling in Drosophila and mammalian cells as well as in Xenopus embryos. The data suggest that PP1 controls Wnt signaling through interaction with, and regulated dephosphorylation of, axin. Inhibition of PP1 leads to enhanced phosphorylation of specific sites on axin by casein kinase I. Axin phosphorylation markedly enhances the binding of glycogen synthase kinase 3, leading to a more active
beta-catenin
destruction complex. Wnt-regulated changes in axin phosphorylation, mediated by PP1, may therefore determine
beta-catenin
transcriptional activity. Specific inhibition of PP1 in this pathway may offer therapeutic approaches to disorders with increased
beta-catenin
signaling.
...
PMID:Protein phosphatase 1 regulates assembly and function of the beta-catenin degradation complex. 1731 75
Pasteurella multocida toxin (PMT) is a potent mitogen and a specific activator of Gq-dependent signalling pathways. PMT impairs osteoblast differentiation and causes bone loss and fat reduction in vivo. We examined the effect of PMT on cell signalling pathways involved in 3T3-L1 adipocyte differentiation. We demonstrate that PMT treatment before or together with differentiation induction factors inhibits adipogenesis and prevents upregulation of important adipocyte markers - peroxisome-proliferator-activated receptor gamma (PPARgamma) and CAATT enhancer-binding protein alpha (C/EBPalpha). Moreover, PMT completely downregulates PPARgamma and C/EBPalpha expression in mature adipocytes. Differentiation of pre-adipocytes into adipocytes requires the suppression of pre-adipocyte factor 1 (Pref1) and Wnt signalling, along with the degradation of
beta-catenin
. PMT prevents downregulation of Pref1 and
beta-catenin
under differentiation-inducing conditions. In addition, PMT treatment downregulates expression of Notch1, a protein responsible for cell fate decision and implicated in regulation of adipogenesis in 3T3-L1 cells. PMT action on adipogenesis was not reversed by cyclosporin A, an inhibitor of Galphaq-PLC-calcium-dependent
calcineurin
activation. Our results reveal new pathways involved in PMT action on cellular physiology and differentiation. Our study further demonstrates that the effect of PMT on Pref1/PPARgamma/C/EBPalpha expression and adipogenesis does not occur just through activation of the Galphaq-calcium-
calcineurin
pathway, but involves Wnt/
beta-catenin
and Notch1 signalling pathways, two signalling pathways strongly linked to cancer predisposition, neurological and immunological dysfunctions, and fat and bone development.
...
PMID:Calcineurin-independent inhibition of 3T3-L1 adipogenesis by Pasteurella multocida toxin: suppression of Notch1, stabilization of beta-catenin and pre-adipocyte factor 1. 1758 Dec 54
To gain further insight into alterations in cellular pathways, tumor profiling, and marker discovery in colorectal cancer (CRC) we used a new antibody microarray specific for cell signaling. Soluble protein extracts were prepared from paired tumor/normal biopsies of 11 patients diagnosed with colorectal carcinoma at different stages; four liver carcinomas were used as a reference. Antibody microarray analysis identified 46 proteins that were differentially expressed between normal colorectal epithelium and adenocarcinoma. These proteins gave a specific signature for CRC, different from other tumors, as well as a panel of novel markers and potential targets for CRC. Twenty-four proteins were validated by using a specific colorectal cancer tissue microarray and immunoblotting analysis. Together with some previously well known deregulated proteins in CRC (
beta-catenin
, c-MYC, or p63), we found new potential markers preferentially expressed in CRC tumors: cytokeratin 13,
calcineurin
, CHK1, clathrin light chain, MAPK3, phospho-PTK2/focal adhesion kinase (Ser-910), and MDM2. CHK1 antibodies were particularly effective in discriminating between tumoral and normal mucosa in CRC. Moreover a global picture of alterations in signaling pathways in CRC was observed, including a significant up-regulation of different components of the epidermal growth factor receptor and Wnt/
beta-catenin
pathways and the down-regulation of p14(ARF). The experimental approach described here should be applicable to other pathologies and neoplastic processes.
...
PMID:A proteomics analysis of cell signaling alterations in colorectal cancer. 1784 89
It was previously observed that cell confluence induced up-regulation of neutral sphingomyelinase 2 (nSMase2) and increased ceramide levels [Marchesini N., Osta W., Bielawski J., Luberto C., Obeid L.M. and Hannun Y.A. (2004) J. Biol. Chem., 279, 25101-11]. In this study, we show that, in MCF7 cells, confluence induces the dephosphorylation of phosphorylated-
beta-catenin
at threonine41/serine45. The effect of confluence on
beta-catenin
dephosphorylation was prevented by down regulation of nSMase2 using siRNA; reciprocally, exogenous addition of short or very long chain ceramides induced dephosphorylation of
beta-catenin
. The serine/threonine
protein phosphatase
inhibitors calyculin A and okadaic acid prevented
beta-catenin
dephosphorylation during confluence. The specific phosphatase involved was determined by studies using siRNA against the major serine/threonine phosphatases, and the results showed that a specific siRNA against PP1cgamma prevented dephosphorylation of
beta-catenin
. Moreover, exogenous ceramides and confluence were found to induce the translocation of PP1cgamma to the plasma membrane. All together these results establish: A) a specific intracellular pathway involving the activation of PP1 to mediate the effects of confluence-induced
beta-catenin
dephosphorylation and B) PP1 as a lipid-regulated
protein phosphatase
downstream of nSMase2/ceramide. Finally, evidence is provided for a role for this pathway in regulating cell motility during confluence.
...
PMID:Confluence induced threonine41/serine45 phospho-beta-catenin dephosphorylation via ceramide-mediated activation of PP1cgamma. 1799 6
Loss or inhibition of the serine/threonine protein phosphatase 2A (
PP2A
) has revealed a critical tumor suppressor function for
PP2A
. However,
PP2A
has also been shown to have important roles in cell cycle progression and survival. Therefore,
PP2A
is not a typical tumor suppressor. This is most likely due to the fact that
PP2A
represents a large number of different holoenzymes. Further understanding of
PP2A
function(s), and especially its tumor suppressor activity, will depend largely on our ability to determine specific targets for these different
PP2A
holoenzymes and to gain an understanding of how these targets confer tumor suppressor activity or contribute to cell cycle progression and cell survival. Recent work has identified c-Myc as a target of the
PP2A
holoenzyme,
PP2A
-B56alpha. This holoenzyme also negatively regulates
beta-catenin
expression and modulates the anti-apoptotic activity of Bcl2, thus characterizing
PP2A
-B56alpha as a tumor suppressor
PP2A
holoenzyme. This review will focus on the role of
PP2A
-B56alpha in regulating c-Myc and will place this tumor suppressor activity of
PP2A
within the context of its other tumor suppressor functions. Finally, the mechanism(s) through which
PP2A
-B56alpha tumor suppressor activity may be lost in cancer will be discussed.
...
PMID:A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. 1824 11
Connective tissue growth factor (CTGF), a member of the CCN family of proteins, is expressed by osteoblasts, but its function in cells of the osteoblastic lineage has not been established. We investigated the effects of CTGF overexpression by transducing murine ST-2 stromal cells with a retroviral vector, where CTGF is under the control of the cytomegalovirus promoter. Overexpression of CTGF in ST-2 cells increased alkaline phosphatase activity, osteocalcin and alkaline phosphatase mRNA levels, and mineralized nodule formation. CTGF overexpression decreased the effect of bone morphogenetic protein-2 on Smad 1/5/8 phosphorylation and of Wnt 3 on cytosolic
beta-catenin
, indicating that the stimulatory effect on osteoblastogenesis was unrelated to BMP and Wnt signaling. CTGF overexpression suppressed Notch signaling and induced the transcription of hairy and E (spl)-1 (HES)-1, by Notch-independent mechanisms. CTGF induced nuclear factor of activated T cells (NFAT) transactivation by a
calcineurin
-dependent mechanism. Down-regulation of CTGF enhanced Notch signaling and decreased HES-1 transcription and NFAT transactivation. Similar effects were observed following forced CTGF overexpression, the addition of CTGF protein, or the transduction of ST-2 cells with a retroviral vector expressing HES-1. In conclusion, CTGF enhances osteoblastogenesis, possibly by inhibiting Notch signaling and inducing HES-1 transcription and NFAT transactivation.
...
PMID:Connective tissue growth factor enhances osteoblastogenesis in vitro. 1858 40
<< Previous
1
2
3
4
Next >>